GlassScriptPhysician profile
Cary N Robertson
NPI 1730242512
$75,830.19
in general payments reported to CMS, 2019-2025
12 companies · $33K in 2025
The $33K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $82.69 · 2021: $40.66 · 2022: $544 · 2023: $32K · 2024: $8,169 · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K · Travel and Lodging: $7,038 · Food and Beverage: $2,804 · Education: $35.06 · Entertainment: $15.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,780.98 |
| Travel and Lodging | $7,037.91 |
| Food and Beverage | $2,803.93 |
| Education | $35.06 |
| Entertainment | $15.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edap Technomed INC | $73,724.33 | 2019-2025 | |
| Janssen Research & Development, LLC | $1,014.12 | 2019 | |
| Angiodynamics, INC. | $266.41 | 2024 | Nanoknife |
| Intuitive Surgical, INC. | $141.96 | 2022-2024 | |
| Astellas Pharma INC | $140.88 | 2024 | Xtandi |
| Pfizer INC. | $134.85 | 2019 | |
| Astellas Pharma US INC | $128.31 | 2019 | |
| Profound Medical Corp. | $78.90 | 2025 | Tulsa-Pro |
| Blue Earth Diagnostics | $76.95 | 2023 | |
| Procept Biorobotics Corporation | $64.00 | 2023 | Aquabeam Robotic System |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Foundation Medicine, INC. | $24.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.